Physician profile
John Rose
NPI 1952625907
$3,046.21
in general payments reported to CMS, 2019-2025
9 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2021: $15.16 · 2022: $348 · 2023: $502 · 2024: $715 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396 · Travel and Lodging: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.59 |
| Travel and Lodging | $343.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $944.66 | 2019 | |
| Intuitive Surgical, INC. | $742.61 | 2022-2024 | Da Vinci Surgical System |
| Exelixis INC. | $307.34 | 2024-2025 | Cabometyx |
| Siemens Medical Solutions USA, INC. | $299.36 | 2024 | Varian Cryocare Touch System, Microthermx Microwave Ablation System |
| Abbvie INC. | $271.15 | 2021-2025 | |
| Integra Lifesciences Corporation | $170.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Somatuline Depot, Onivyde |
| Ethicon US, LLC | $143.20 | 2025 | Harmonic, Enseal |
| Astrazeneca Pharmaceuticals Lp | $17.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.